Perivascular spaces, plasma GFAP, and speeded executive function in neurodegenerative diseases

Alzheimers Dement. 2024 Aug;20(8):5800-5808. doi: 10.1002/alz.14081. Epub 2024 Jul 4.

Abstract

Introduction: We investigated the effect of perivascular spaces (PVS) volume on speeded executive function (sEF), as mediated by white matter hyperintensities (WMH) volume and plasma glial fibrillary acidic protein (GFAP) in neurodegenerative diseases.

Methods: A mediation analysis was performed to assess the relationship between neuroimaging markers and plasma biomarkers on sEF in 333 participants clinically diagnosed with Alzheimer's disease/mild cognitive impairment, frontotemporal dementia, or cerebrovascular disease from the Ontario Neurodegenerative Disease Research Initiative.

Results: PVS was significantly associated with sEF (c = -0.125 ± 0.054, 95% bootstrap confidence interval [CI] [-0.2309, -0.0189], p = 0.021). This effect was mediated by both GFAP and WMH.

Discussion: In this unique clinical cohort of neurodegenerative diseases, we demonstrated that the effect of PVS on sEF was mediated by the presence of elevated plasma GFAP and white matter disease. These findings highlight the potential utility of imaging and plasma biomarkers in the current landscape of therapeutics targeting dementia.

Highlights: Perivascular spaces (PVS) and white matter hyperintensities (WMH) are imaging markers of small vessel disease. Plasma glial fibrillary protein acidic protein (GFAP) is a biomarker of astroglial injury. PVS, WMH, and GFAP are relevant in executive dysfunction from neurodegeneration. PVS's effect on executive function was mediated by GFAP and white matter disease.

Keywords: cerebrovascular diseases; executive function; neurodegenerative diseases; perivascular spaces; plasma glial fibrillary acidic protein; white matter hyperintensities.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Alzheimer Disease / blood
  • Alzheimer Disease / pathology
  • Biomarkers* / blood
  • Brain / diagnostic imaging
  • Brain / pathology
  • Cerebrovascular Disorders / blood
  • Cerebrovascular Disorders / diagnostic imaging
  • Cerebrovascular Disorders / pathology
  • Cognitive Dysfunction / blood
  • Cohort Studies
  • Executive Function* / physiology
  • Female
  • Frontotemporal Dementia / blood
  • Frontotemporal Dementia / diagnostic imaging
  • Frontotemporal Dementia / pathology
  • Glial Fibrillary Acidic Protein* / blood
  • Glymphatic System* / diagnostic imaging
  • Glymphatic System* / pathology
  • Humans
  • Magnetic Resonance Imaging*
  • Male
  • Middle Aged
  • Neurodegenerative Diseases* / blood
  • White Matter* / diagnostic imaging
  • White Matter* / pathology

Substances

  • Glial Fibrillary Acidic Protein
  • Biomarkers
  • GFAP protein, human

Grants and funding